CIPLA.BO : Summary for CIPLA LTD. - Yahoo Finance

U.S. Markets closed

Cipla Limited (CIPLA.BO)


BSE - BSE Delayed Price. Currency in INR
Add to watchlist
591.60+3.75 (+0.64%)
At close: 3:51PM IST
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close587.85
Open590.00
Bid0.00 x
Ask0.00 x
Day's Range586.00 - 595.00
52 Week Range458.25 - 621.90
Volume37,139
Avg. Volume95,490
Market Cap475.28B
BetaN/A
PE Ratio (TTM)31.65
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Cipla Ltd. breached its 50 day moving average in a Bearish Manner : 500087-IN : February 16, 2017
    Capital Cube9 days ago

    Cipla Ltd. breached its 50 day moving average in a Bearish Manner : 500087-IN : February 16, 2017

    Categories: Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Cipla Ltd.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average ... Read more (Read more...)

  • Cipla Ltd. :500087-IN: Earnings Analysis: Q3, 2017 By the Numbers : February 13, 2017
    Capital Cube11 days ago

    Cipla Ltd. :500087-IN: Earnings Analysis: Q3, 2017 By the Numbers : February 13, 2017

    Categories: Yahoo Finance Get free summary analysis Cipla Ltd. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Cipla Ltd. – Dr. Reddy’s Laboratories Ltd., Cadila Healthcare Limited and Wockhardt Limited (500124-IN, 532321-IN and 532300-IN) that have also reported for this period. Highlights Summary numbers: Revenues of ... Read more (Read more...)

  • Reuters16 days ago

    India's Cipla looks to boost US business as Q3 profit beats estimates

    Indian drugmaker Cipla Ltd's third-quarter profit beat estimates due to higher sales in the United States, and the company said it was looking for licensing deals and acquisitions to build its speciality medicines pipeline in that market. The country's fifth-largest drugmaker by sales reported a roughly 21 percent rise in revenue from North America for the October-December period. Cipla bought two U.S. generic drug producers, Invagen and Exelan, for about $550 million last year in its first big move to expand in a market where most of its local peers already have a large presence.